The upregulation and overexpression of Placental Growth Factor (PIGF) in CRC cases that exhibit resistance to anti-angiogenic therapies indicates the critical role of PIGF as a contributing factor in the development of resistance to anti-VEGF treatments [18]. This evidence concerns the gene PIGF and colorectal carcinoma.